MX2016007122A - Peptidos derivados de ezrina y composiciones farmaceuticas de los mismos. - Google Patents
Peptidos derivados de ezrina y composiciones farmaceuticas de los mismos.Info
- Publication number
- MX2016007122A MX2016007122A MX2016007122A MX2016007122A MX2016007122A MX 2016007122 A MX2016007122 A MX 2016007122A MX 2016007122 A MX2016007122 A MX 2016007122A MX 2016007122 A MX2016007122 A MX 2016007122A MX 2016007122 A MX2016007122 A MX 2016007122A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- tract
- ezrin
- pharmaceutical compositions
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4735—Villin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al campo de la medicina, específicamente, al campo de la industria química y farmacéutica, y se refiere a péptidos derivados de ezrina, en particular, un péptido que comprende una secuencia de aminoácidos de formula general (I) X1 EKKRRETVERE X2X3, en la que cada X representa un residuo de aminoácido no polar. El uso de los péptidos como agentes inmunoestimulantes y más específicamente, para su uso en el tratamiento y la prevención de infecciones antivirales, antibacterianas y antifúngicas, y el tratamiento de enfermedades del tracto GI, en particular trastornos ulcerativos del tracto GI. La presente invención también se refiere a composiciones farmacéuticas que comprenden los péptidos. Además, la invención se refiere a métodos de tratamiento de infección y enfermedades ulcerativas del tracto GI que comprenden administrar los péptidos a pacientes en necesidades de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015120667 | 2015-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007122A true MX2016007122A (es) | 2017-01-25 |
Family
ID=56117690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007122A MX2016007122A (es) | 2015-06-01 | 2016-06-01 | Peptidos derivados de ezrina y composiciones farmaceuticas de los mismos. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9682140B2 (es) |
| EP (1) | EP3191504B1 (es) |
| JP (1) | JP6721419B2 (es) |
| KR (1) | KR101842978B1 (es) |
| CN (1) | CN106188267B (es) |
| AU (1) | AU2016203656B2 (es) |
| BR (1) | BR102016012501A2 (es) |
| CA (1) | CA2931875C (es) |
| CY (1) | CY1120501T1 (es) |
| DK (1) | DK3191504T3 (es) |
| ES (1) | ES2660894T3 (es) |
| GB (1) | GB2546439B (es) |
| HR (1) | HRP20180560T1 (es) |
| HU (1) | HUE038737T2 (es) |
| LT (1) | LT3191504T (es) |
| MA (1) | MA39421A (es) |
| MD (1) | MD3191504T2 (es) |
| ME (1) | ME03033B (es) |
| MX (1) | MX2016007122A (es) |
| PL (1) | PL3191504T3 (es) |
| PT (1) | PT3191504T (es) |
| RS (1) | RS57067B1 (es) |
| SG (1) | SG10201604401UA (es) |
| SI (1) | SI3191504T1 (es) |
| WO (1) | WO2016193285A1 (es) |
| ZA (1) | ZA201603723B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
| CN106596977B (zh) * | 2017-02-08 | 2018-06-08 | 南京医科大学第一附属医院 | ezrin在制备哮喘诊断试剂中的应用 |
| WO2021198346A2 (en) | 2020-04-01 | 2021-10-07 | Dr. Nesselhut Besitzgesellschaft Mbh | Ezrin peptide 1 for use in a method of treating covid-19 |
| JP2024511660A (ja) | 2021-03-31 | 2024-03-14 | パンタファルム・アー・ゲー | ポストｃｏｖｉｄ－１９を治療する方法における使用のためのエズリンペプチド１ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2290293A (en) * | 1994-06-08 | 1995-12-20 | Rupert Donald Holms | Preparation which inhibits the autoimmune response in HIV, or SLE, patients |
| GB2354241A (en) * | 1999-09-17 | 2001-03-21 | Rupert Donald Holms | Regulatory/unfolding peptides of ezrin |
| GB0301879D0 (en) | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
| WO2007060440A2 (en) | 2005-11-23 | 2007-05-31 | Regent Research L.L.P. | The use of peptides in anti-ulcer therapy |
-
2016
- 2016-06-01 BR BR102016012501A patent/BR102016012501A2/pt active IP Right Grant
- 2016-06-01 MA MA039421A patent/MA39421A/fr unknown
- 2016-06-01 LT LTEP16728271.4T patent/LT3191504T/lt unknown
- 2016-06-01 PT PT167282714T patent/PT3191504T/pt unknown
- 2016-06-01 CA CA2931875A patent/CA2931875C/en active Active
- 2016-06-01 WO PCT/EP2016/062336 patent/WO2016193285A1/en active Application Filing
- 2016-06-01 DK DK16728271.4T patent/DK3191504T3/en active
- 2016-06-01 GB GB1705990.8A patent/GB2546439B/en active Active
- 2016-06-01 SG SG10201604401UA patent/SG10201604401UA/en unknown
- 2016-06-01 MX MX2016007122A patent/MX2016007122A/es active IP Right Grant
- 2016-06-01 SI SI201630027T patent/SI3191504T1/en unknown
- 2016-06-01 KR KR1020160068187A patent/KR101842978B1/ko active IP Right Grant
- 2016-06-01 PL PL16728271T patent/PL3191504T3/pl unknown
- 2016-06-01 US US15/170,362 patent/US9682140B2/en active Active
- 2016-06-01 HU HUE16728271A patent/HUE038737T2/hu unknown
- 2016-06-01 JP JP2016110444A patent/JP6721419B2/ja active Active
- 2016-06-01 ES ES16728271.4T patent/ES2660894T3/es active Active
- 2016-06-01 RS RS20180392A patent/RS57067B1/sr unknown
- 2016-06-01 AU AU2016203656A patent/AU2016203656B2/en active Active
- 2016-06-01 ME MEP-2018-96A patent/ME03033B/me unknown
- 2016-06-01 MD MDE20170043T patent/MD3191504T2/ro unknown
- 2016-06-01 CN CN201610384013.2A patent/CN106188267B/zh active Active
- 2016-06-01 EP EP16728271.4A patent/EP3191504B1/en active Active
- 2016-06-01 ZA ZA2016/03723A patent/ZA201603723B/en unknown
-
2018
- 2018-03-26 CY CY20181100335T patent/CY1120501T1/el unknown
- 2018-04-06 HR HRP20180560TT patent/HRP20180560T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
| GB2546439A (en) | Ezrin-derived peptides and pharmaceutical compositions thereof | |
| EA201990949A1 (ru) | Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине | |
| MX2017016227A (es) | Peptidos anti-infecciosos de amplio espectro. | |
| MX2019014876A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| BR112018070819A2 (pt) | peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo | |
| PH12021551280A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MX2021006489A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| EA201991233A1 (ru) | Новый эндолизин | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
| MX2019006768A (es) | Peptidos antimicrobianos. | |
| WO2015043566A8 (de) | Zyklische, amyloid-beta-bindende peptide und deren verwendung | |
| NZ700467A (en) | Treatments suitable for malassezia infections | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| MX2022000433A (es) | Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv. | |
| MX2018011095A (es) | Compuestos de carbapenem. | |
| MY197042A (en) | Compounds | |
| MY184269A (en) | Broad-spectrum anti-influenza virus therapeutic peptides | |
| PH12017501943A1 (en) | Influenza virus neutralizing peptidomimetic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: NEWALR&D LTD |